The impact of the Covid-19 pandemic on breast cancer early detection and screening.
Breast
COVID-19
Incidence
Modelling
Mortality
Screening
Journal
Preventive medicine
ISSN: 1096-0260
Titre abrégé: Prev Med
Pays: United States
ID NLM: 0322116
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
10
02
2021
revised:
22
04
2021
accepted:
25
04
2021
entrez:
4
7
2021
pubmed:
5
7
2021
medline:
9
7
2021
Statut:
ppublish
Résumé
The COVID-19 pandemic affects mortality and morbidity, with disruptions expected to continue for some time, with access to timely cancer-related services a concern. For breast cancer, early detection and treatment is key to improved survival and longer-term quality of life. Health services generally have been strained and in many settings with population breast mammography screening, efforts to diagnose and treat breast cancers earlier have been paused or have had reduced capacity. The resulting delays to diagnosis and treatment may lead to more intensive treatment requirements and, potentially, increased mortality. Modelled evaluations can support responses to the pandemic by estimating short- and long-term outcomes for various scenarios. Multiple calibrated and validated models exist for breast cancer screening, and some have been applied in 2020 to estimate the impact of breast screening disruptions and compare options for recovery, in a range of international settings. On behalf of the Covid and Cancer Modelling Consortium (CCGMC) Working Group 2 (Breast Cancer), we summarize and provide examples of such in a range of settings internationally, and propose priorities for future modelling exercises. International expert collaborations from the CCGMC Working Group 2 (Breast Cancer) will conduct analyses and modelling studies needed to inform key stakeholders recovery efforts in order to mitigate the impact of the pandemic on early diagnosis and treatment of breast cancer.
Identifiants
pubmed: 34217412
pii: S0091-7435(21)00169-9
doi: 10.1016/j.ypmed.2021.106585
pmc: PMC8241687
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106585Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Références
JCO Glob Oncol. 2020 Sep;6:1419-1421
pubmed: 32970486
Lancet Oncol. 2020 Aug;21(8):1035-1044
pubmed: 32702311
J Hematol Oncol. 2020 Nov 4;13(1):147
pubmed: 33148289
Br J Cancer. 2020 Sep;123(5):852-859
pubmed: 32555534
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Cancer. 2016 Feb 1;138(3):705-13
pubmed: 26264446
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
BMC Cancer. 2019 May 10;19(1):432
pubmed: 31077162
JAMA Oncol. 2017 Nov 01;3(11):1563-1567
pubmed: 28542677
JAMA. 2015 Oct 20;314(15):1615-34
pubmed: 26501537
Nat Rev Clin Oncol. 2020 Nov;17(11):687-705
pubmed: 32555420
BMC Health Serv Res. 2020 Mar 18;20(1):228
pubmed: 32183801
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):344-352
pubmed: 33412828
Lancet Oncol. 2020 Jun;21(6):750-751
pubmed: 32359403
Cancer. 2020 May 15;126 Suppl 10:2416-2423
pubmed: 32348572
Public Health Res Pract. 2020 Dec 9;30(4):
pubmed: 33294902
J Med Screen. 2021 Jun;28(2):100-107
pubmed: 33241760
Br J Cancer. 2021 Feb;124(4):710-712
pubmed: 33250510
Asia Pac J Clin Oncol. 2021 Aug;17(4):359-367
pubmed: 33567163
PLoS Med. 2019 Dec 31;16(12):e1003006
pubmed: 31891574
Radiol Clin North Am. 2021 Jan;59(1):1-11
pubmed: 33222992
Br J Cancer. 2013 Jun 11;108(11):2205-40
pubmed: 23744281
Br J Cancer. 2021 Apr;124(9):1516-1523
pubmed: 33723386
JAMA Oncol. 2016 Mar;2(3):330-9
pubmed: 26659430
In Vivo. 2020 Sep-Oct;34(5):3047-3053
pubmed: 32871851
Cancer. 2020 Dec 15;126(24):5202-5205
pubmed: 32914864
Nat Rev Clin Oncol. 2020 Jun;17(6):329-331
pubmed: 32296166